Skip to main content
. 2016 Jul 29;7(35):56976–56985. doi: 10.18632/oncotarget.10927

Figure 4. Telomere length and shelterin expression predict progression-free survival (PFS) in patients with wild-type (wt) TP53.

Figure 4

A. Kaplan–Meier estimates of PFS in the whole patient population as a function of TP53 status and the wild-type TP53 cohort according to telomere length B. POT1 C. TPP1 D. and TIN2 E. levels. The optimal cut-off values were determined using recursive partitioning. CLL patients with short telomeres and low POT1, TPP1 and TIN2 levels had significantly shorter PFSs. F. Corresponding hazard ratios (HR) and 95%-confidence intervals (95%CI) are presented. When adjusted for telomere length and IGHV mutation profile, low POT1, TPP1 and TIN2 expression remained significant predictors for a shorter PFS.